Psychostimulant drugs for cocaine dependence

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Castells, Xavier ^a   Cunill, Ruth ^b   Pérez Mañá, Clara ^c   Vidal, Xavier ^d   Capellà, Dolors ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; COCAINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; MAZINDOL; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT; SELEGILINE;

ATTENTION DEFICIT DISORDER; BIOMED CENTRAL; CARDIOVASCULAR DISEASE; COCAINE DEPENDENCE; COCHRANE LIBRARY; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED PRACTICE; HEROIN DEPENDENCE; HUMAN; MEDLINE; META ANALYSIS; OPIATE ADDICTION; PATIENT DROPOUT; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84988825992     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007380.pub4     Document Type: Review

References (152)

1. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, et al. Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence 2009;104(1-2):133-9.
2. Dackis CA, Kampman KM, Lynch KG, Pettinati H, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30(1):205-11.
3. Starosta AN, Rha C, Whitingham T. Factors involved in predicting the success of modafinil for the treatment of cocaine-dependent subjects. 68th Annual Scientific Meeting of the College on Problems of Drug Dependence 2006 June 17-22:www.cpdd.org/Pages/Meetings/Meetings_PDFs/2006abstractbook.pdf: College on Problems of Drug Dependence, 2006:186.
4. Dackis CA, Kampman KM, Lynch KG, Plebani JG, Pettinati HM, Sparkman T, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Journal of Substance Abuse Treatment 2012;43(3):303-12.
5. Dürsteler-MacFarland KM, Farronato NS, Strasser J, Boss J, Kuntze MF, Petitjean SA, et al. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription. Journal of Clinical Pharmacology 2013;33(1):104-8.
6. Elkashef A, Fudala PJ, Gordon L, Li S-H, Kahn R, Chiang N, et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug and Alcohol Dependence 2006;85(3):191-7.
7. Grabowki J, Schmitz J, Roache JD, Rhoades H, Elk R, Creson DL. Methylphenidate (MP) for initial treatment of cocaine dependence and a model for medication evaluation. NIDA Research Monograph 1994;141:436.
8. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. Journal of Clinical Psychopharmacology 1997;17(6):485-8.
9. Grabowski J, Rhoades H, Schmitz J, Stotts A, AnnDaruzska L, Creson D, et al. Dextroamphetamine for cocaine-dependence treatment:a double-blind randomised clinical trial. Journal of Clinical Psychopharmacology 2001;21(5):522-6.
10. Grabowski J, Rhoades H, Scotts A, Cowan K, Kopecky C, Dougherty A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29(5):969-81.
11. Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C, et al. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug and Alcohol Dependence 2015;155(Oct):105-10.
12. Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, et al. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence effects on outcome. American Journal of Drug and Alcohol Abuse 2006;32(4):629-35.
13. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence 2007;87(1):20-9.
14. Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry 2015;72(6):593-602.
15. Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug and Alcohol Dependence 1995;40(2):125-31.
16. Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. American Journal of Drug and Alcohol Abuse 1995;21(4):469-81.
17. Margolin A, Avants K, Malison RT, Kosten TR. High- and low-dose mazindol for cocaine dependence in methadone-maintained patients:a preliminary evaluation. Substance Abuse 1997;18(3):125-31.
18. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2009;101(1-2):34-41.
19. Mooney ME, Herin DV, Specker S, Babb D, Levin FR, Grabowski J. Pilot study of the effects of lisdexamfetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2015;153(Aug):94-103.
20. Morgan PT, Angarita GA, Canavan S, Pittman B, Oberleitner L, Malison RT, et al. Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. Drug and Alcohol Dependence 2015;160(Mar):49-56.
21. NCT00142818 Modafinil and naltrexone to reduce cocaine and alcohol dependence (Mod-Nal). clinicaltrials.gov/show/NCT00142818 (first received 1 September 2005).
22. Perry EB, Gil R, Miles D, Brenner L, MacDougall L, Johson R, et al. Mazindol augmentation of antipsychotic treatment for schizophrenic patients with comorbid cocaine abuse or dependence: a preliminary double-blind, randomized, placebo-controlled trial. Journal of Dual Diagnosis 2004;1(1):37-47.
23. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry 2006;63(2):219-28.
24. Schmitz JM, Rathnayaka N, Green CE, Moeller FG, Dougherty AE, Grabowski J. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Frontiers in Psychiatry/Frontiers Research Foundation 2012;3(Aug):77.
25. Schmitz JM, Green CE, Stotts AL, Lindsay JA, Rathnayaka NS, Grabowski J, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone. Drug and Alcohol Dependence 2014;136(Mar):100-7.
26. Downey KK, Schubiner H, Schuster CR. Double-blind placebo controlled stimulant trial for cocaine dependent ADHD adults. NIDA Research Monograph 2000;180:116.
27. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology 2002;10(3):286-94.
28. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98(8):1137-41.
29. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang P-C, Bholat MA, et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal of Addictive Diseases 2008;27(1):13-23.
30. Stine SM, Krystal JH, Kosten TR, Charney DS. Mazindol treatment for cocaine dependence. Drug and Alcohol Dependence 1995;39(3):245-52.
31. Afshar M, Knapp CM, Sarid-Segal O, Devine E, Colaneri LS, Tozier L, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. American Journal of Drug and Alcohol Abuse 2012;38(2):181-6.
32. Avants SK, Margolin A, DePhilippis D, Kosten TR. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine-and-opioid-dependent patients. Preliminary findings. Journal of Substance Abuse Treatment 1998;15(3):261-5.
33. Berger P, Gawin F, Kosten TR. Treatment of cocaine abuse with mazindol. Lancet 1989;1(8632):283.
34. Canavan SV, Forselius EL, Bessette AJ, Morgan PT. Preliminary evidence for normalization of risk taking by modafinil in chronic cocaine users. Addict Behaviors 2014;39(6):1057-61.
35. Goldstein RZ, Woicik PA, Moeller SJ, Telang F, Jayne M, Wong C, et al. Liking and wanting of drug and non-drug rewards in active cocaine users: the STRAP-R questionnaire. Journal of Psychopharmacology 2010;24(2):257-66.
36. Goldstein RZ, Volkow ND. Oral methylphenidate normalizes cingulate activity and decreases impulsivity in cocaine addiction during an emotionally salient cognitive task. Neuropsychopharmacology 2011;36(1):366-7.
37. Herin DV. Agonist-like medications for cocaine dependence treatment: clinical studies. Neuropsychopharmacology 2010;35(Supplement):S21.
38. Kalechstein A, Mahoney J, Bennett R, Shah RS, Yoon J, Chang LC, et al. Short-term modafinil administration improves working memory and sustained attention in cocaine-dependent volunteers. Neuropsychopharmacology 2011;36(Supplement):S176.
39. Kalechstein AD, Mahoney JJ 3rd, Yoon JH, Bennett R, De la Garza R 2nd. Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology 2013;64(Jan):472-8.
40. Kampman KM, Volpicelli J. Combination of the dopaminergic agent, phentermine, and the serotoninergic agent, fenfluramine, in the treatment of cocaine dependence. Journal of Substance Abuse Treatment 1997;14(4):401-4.
41. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. Journal of Clinical Psychiatry 1998;59(6):300-5.
42. Levin FR, Evans SM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder. NIDA Research Monograph 1999;179:39.
43. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence 2006;81(2):137-48.
44. Levin FR, Bisaga A, Raby W, Aharonovich E, Rubin E, Mariani J, et al. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. Journal of Substance Abuse Treatment 2008;34(1):80-9.
45. Magee JC, Lewis DF, Winhusen T. Evaluating nicotine craving, withdrawal, and substance use as mediators of smoking cessation in cocaine- and methamphetamine-dependent patients. Nicotine & Tobacco Research 2015;18(5):1196-201.
46. Magee JC, Winhusen T. The coupling of nicotine and stimulant craving during treatment for stimulant dependence. Journal of Consulting and Clinical Psychology 2016;84(3):230-7.
47. Margolin A, Kosten T, Petrakis I, Avants SK, Kosten T. Bupropion reduces cocaine abuse in methadone-maintained patients. Archives of Geneneral Psychiatry 1991;48(1):87.
48. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biological Psychiatry 2012;72(11):950-6.
49. Moeller FG, Steinberg JL, Lane SD, Ma L, Kosten TR, Narayana PA. Pharmacological MRI of d-amphetamine: effects of a go-no/go task in cocaine dependent subjects. Neuropsychopharmacology 2011;36(Supplement):S285.
50. Moeller SJ, Honorio J, Tomasi D, Parvaz MA, Woicik PA, Volkow ND, et al. Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction. Cerebral Cortex 2014;24(3):643-53.
51. Montoya ID, Preston KL, Rothman R, Cone E, Gorelick DA. Safety and efficacy of bupropion in combination with bromocriptine for treatment of cocaine dependence. NIDA Research Monograph 1994;153:304.
52. Mooney ME, Poling J, Gonzalez G, Gonsai K, Kosten T, Sofluoglu M. Preliminary study of buprenorphine and bupropion for opioid dependent smokers. American Journal on Addictions 2008;17(4):287-92.
53. Morgan PT, Pace-Schott E, Pittman B, Stickgold R, Malison RT. Normalizing effects of modafinil on sleep in chronic cocaine users. American Journal of Psychiatry 2010;167(3):331-40.
54. Nuijten M, Blanken P, van den Brink W, Hendriks V. Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial. Journal of Psychopharmacology 2015;29(6):678-87.
55. Ollo C, Alim TN, Rosse RB, Lindquist T, Green T, Gillis T, et al. Lack of neurotoxic effect of diethylpropion in crack-cocaine abusers. Clinical Neuropharmacology 1996;19(1):52-8.
56. Peirce JM, Petry NM, Roll JM, Kolodner K, Krasnansky J, Stabile PQ, et al. Correlates of stimulant treatment outcome across treatment modalities. The American Journal of Drug and Alcohol Abuse 2009;35(1):48-53.
57. Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. The American Journal on Addictions 2010;19(5):401-8.
58. Rush CR, Stoops WW, Sevak RJ, Hays LR. Cocaine choice in humans during D-amphetamine maintenance. Journal of Clinical Psychopharmacology 2010;30(2):152-9.
59. Seibyl JP, Brenner L, Krystal JH, Johson R, Charney DS. Mazindol and cocaine addiction in schizophrenia. Biological Psychiatry 1992;31(11):1179-81.
60. Shearer J, Shanahan M, Darke S, Rodgers C, Van Beek I, McKetin R, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug and Alcohol Review 2010;39(3):235-42.
61. Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug and Alcohol Dependence 2013;131(1):66-70.
62. Tennant F. Clinical trial of multiple treatment agents for cocaine dependence: a placebo-controlled elimination study. NIDA Research Monograph 1990;105:512-3.
63. Vansickel AR, Fillmorex MT, Hays LR, Rush CR. Effects of potential agonist-replacement therapies for stimulant dependence on inhibitory control in cocaine abusers. American Journal of Drug and Alcohol Abuse 2008;34(3):293-305.
64. Volkow N. Decreased motivation in ADHD is associated with deficit in dopamine reward pathway. Neuropsychopharmacology 2010;35(Supplement):S39.
65. Vosburg SK, Hart CL, Haney M, Rubin E, Foltin RW. Modafinil does not serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence 2010;15(2):233-6.
66. Wang GJ, Volkow N, Telang F, Tomasi D, Logan J, Wong C, et al. Decreased striatal and prefrontal dopaminergic responses in active cocaine dependent subjects. Neuropsychopharmacology 2010;35(Supplement):S372.
67. Winhusen T, Lewis D, Adinoff B, Brigham G, Kropp F, Donovan DM, et al. Impulsivity is associated with treatment non-completion in cocaine- and methamphetamine-dependent patients but differs in nature as a function of stimulant-dependence diagnosis. Journal of Substance Abuse Treatment 2013;44(5):541-7.
68. Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG 2nd, Penn P, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. Journal of Clinical Psychiatry 2014;75(4):336-43.
69. EudraCT 2013-004024-11. New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands: A double-blind, placebo-controlled randomized feasibility study of sustained release dexamphetamine. www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004024-11 (first received 1 September 2014).
70. NCT00015223 Methylphenidate in the treatment of cocaine dependent patients with adult attention deficit hyperactivity disorder. clinicaltrials.gov/show/NCT00015223 (first received 18 April 2001).
71. NCT00218348 Treatment of cocaine dependence: comparison of three doses of dextro-amphetamine sulfate and placebo. clinicaltrials.gov/show/NCT00218348 (first received 15 September 2005).
72. NCT00218387 Modafinil combined with cognitive behavior therapy to treat cocaine addiction. clinicaltrials.gov/show/study/NCT00218387 (first received 16 September 2005).
73. NCT00344565 A placebo-controlled double-blind combined treatment of modafinil and CBT for cocaine dependence. clinicaltrials.gov/show/NCT00344565 (first received 26 June 2006).
74. NCT00495092 Efficacy of caffeine, with and without biperiden, in the detoxification of cocaine dependent patients. clinicaltrials.gov/show/NCT00495092 (first received 29 June 2007).
75. NCT00514202 Pilot study examining effect for dextroamphetamine to treat cocaine dependence plus attention-deficit hyperactivity disorder (ADHD). clinicaltrials.gov/ct2/show/NCT00514202 (first received 07 August 2007).
76. NCT00701532 Brain imaging study of the effects of modafinil in cocaine addiction. clinicaltrials.gov/ct2/show/NCT00701532 (First received: 18 June 2008).
77. NCT00733993 Caffeine and cocaine. clinicaltrials.gov/show/NCT00733993 (first received 12 August 12 2008).
78. NCT00838981 Pharmacotherapy and CM for opioid and cocaine dependence. clinicaltrials.gov/show/NCT00838981 (first received 6 February 2009).
79. NCT00218036 Pharmacotherapy dosing regimen in cocaine and opiate dependent individuals - 8 [Pharmacotherapy dosing regimen in cocaine and opiate dependent individuals]. clinicaltrials.gov/show/NCT00218036 (first received 16 September 2005).
80. NCT02111798 Bupropion-enhanced contingency management for cocaine dependence [Bupropion-enhanced CM for cocaine dependence]. clinicaltrials.gov/ct2/show/NCT02111798 (first received 28 March 2014).
81. NTC00123383 Randomized placebo-controlled trial of modafinil for cocaine dependence [Randomized placebo-controlled trial of modafinil for cocaine dependence]. clinicaltrials.gov/ct2/show/NTC00123383 (first received 21 July 2005).
82. American Society of Health-System Pharmacists. AHFS. American Hospital Formulary Service. Drug Information 2009. Bethesda: American Society of Health-System Pharmacists, 2014.
83. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Publishing, 2000.
84. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: American Psychiatric Publishing, 2013.
85. World Health Organization. ATC/DDD Index. www.whocc.no/atcddd/indexdatabase/ (accessed prior to 25 August 2016).
86. Brayfield A. Martindale: The Complete Drug Reference. 38. Pharmaceutical Press, 2014.
87. Brunton L, Chabner B. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. McGraw Hill, 2011.
88. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Archives of General Psychiatry 2004;61(3):264-72.
89. Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomised controlled clinical trials. Addiction 2007;1002(12):1871-87.
90. Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials. The American Journal of Drug and Alcohol Abuse 2009;35(5):339-49.
91. Cunningham CO, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. American Journal of Addictions 2013;22(4):352-357.
92. Cousins MS, Stamat HM, De Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology 2001;157(3):243-5.
93. Craft RM, Stratmann JA. Discriminative stimulus effects of cocaine in female versus male rats. Drug and Alcohol Dependence 1996;42(1):27-37.
94. Cunill R, Castells X, Tobias A, Capellà D. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. Journal of Psychopharmacology 2015;29(1):15-23.
95. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. European Journal of Pharmacology 2007;568(1-3):112-23.
96. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Reviews 2006;12(3-4):178-207.
97. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315(7109):629-34.
98. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. Trends and developments. www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf (accessed prior to 25 August 2016).
99. Engberg G, Elebring T, Nissbrandt H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Journal of Pharmacology and Experimental Therapeutics 1991;259(2):841-47.
100. Evans SM, Johanson CE. Amphetamine-like effects of anorectics and related compounds in pigeons. The Journal of Pharmacology and Experimental Therapeutics 1987;241(3):817-25.
101. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs 2004;64(14):1547-73.
102. Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 2004;29(7):1439-64.
103. The GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):149.
104. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
105. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
106. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction 2014;109(9):1414-25.
107. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
108. Jasinski DR, Kovacević-Ristanović R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clinical Neuropharmacology 2000;23(3):149-56.
109. Jüni P, Altman DG, Egger M. Assessing the quality of clinical trials. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care. Meta Analysis in Context. London: BMJ publishing group, 2001:87-108.
110. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. American Journal of Psychiatry 2005;162(8):1403-13.
111. Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. American Journal on Addictions 2007;16(2):71-8.
112. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 2004;75(3):233-40.
113. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, et al. New treatments for cocaine dependence: a focused review. International Journal of Neuropsychopharmacology 2008;11(3):425-38.
114. Katz JL, Izenwasser S, Terry P. Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology 2000;148(1):90-8.
115. Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug and Alcohol Dependence 2004;74(2):115-22.
116. Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, et al. American Psychiatric Association Steering Committee on Practice Guidelines. Treatment of patients with substance use disorders, second edition. American Journal of Psychiatry 2007;164(4 Suppl):5-123.
117. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242(4879):715-23.
118. Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. American Journal on Addictions 2005;14(1):8-17.
119. Langguth B, Hajak G, Landgrebe M, Unglaub W. Abuse potential of bupropion nasal insufflation: a case report. Journal of Clinical Psychopharmacology 2009;29(6):618-9.
120. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biological Psychiatry 2003;54(8):800-5.
121. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003;98(1):7-22.
122. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. Journal of Pharmacology and Experimental Therapeutics 2006;319(2):561-9.
123. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clinical Pharmacokinetics 1997;33(2):91-102.
124. Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral andsubjective effects of d-amphetamine and modafinil in healthy adults. Experimental and Clinical Psychopharmacology 2007;15(2):123-33.
125. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD002209]
126. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, Issue CD002209. [DOI: 10.1002/14651858.CD002209.pub2]
127. McCormick J. Recreational bupropion abuse in a teenager. British Journal of Clinical Pharmacology 2002;53(2):214.
128. McDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, et al. Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. Drug and Alcohol Dependence 2005;80(2):209-21.
129. Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD003352.pub4]
130. Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD006754.pub4]
131. Moeller FG, Schmitz JM, Herin D, Kjome KL. Use of stimulants to treat cocaine and methamphetamine abuse. Current Psychiatry Reports 2008;10(5):385-91.
132. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD002950.pub3]
133. Pérez de los Cobos J, Siñol N, Pérez V, Trujols J. Pharmacological and clinical dilemmas of prescribing in comorbid adult attention deficit/hyperactivity disorder and addiction. British Journal of Clinical Pharmacology 2014;77(2):337-56.
134. Redolat R, Vidal J, Gomez MC, Carrasco MC. Effects of acute bupropion administration on locomotor activity in adolescent and adult mice. Behavioral Pharmacology 2005;16(1):59-62.
135. Substance Abuse and Mental Health Services Administration (SAMSHA). Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. Available from: www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf (accessed prior to 25 August 2016).
136. Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug and Alcohol Dependence 2008;94(1):142-50.
137. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation. Health Research Policy & Systems 2006;4(1):26.
138. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metabolism and Disposition 1997;25(6):657-62.
139. United Nations Office on Drug and Crime. World Drug Report. www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf (accessed prior to 25 August 2016).
140. Van Emmerik-Van Oortmerssen K, Van de Glind G, Van den Brink W, Smit F, Crunelle CL, Swets M, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug and Alcohol Dependence 2012;122(1-2):11-9.
141. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. American Journal of Psychiatry 190;147(6):719-24.
142. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemannn R, Gatley SJ, et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 1996;14(3):159-68.
143. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386(6627):827-30.
144. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386(6627):830-3.
145. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular Psychiatry 2004;9(6):557-69.
146. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. Journal of the American Medical Association 2009;301(11):1148-54.
147. World Anti-Doping Agency. List of Prohibited Substances and Methods (available from: http://list.wada-ama.org/). Internet resource 2016.
148. Welsh CJ, Doyon S. Seizure induced by insufflation of bupropion. New England Journal of Medicine 2002;347(12):951.
149. Yasar S, Justinova Z, Lee SH, Stefanski R, Goldberg SR, Tanda G. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. Journal of Pharmacology and Experimental Therapeutics 2006;317(1):387-94.
150. Yasar S, Gaál J, Panlilio LV, Justinova Z, Molnár SV, Redhi GH, et al. A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology 2006;183(4):413-21.
151. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. Journal of Pharmacology and Experimental Therapeutics 2009;329(2):738-46.
152. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2010, Issue CD007380. [DOI: 10.1002/14651858.CD007380.pub3]